Why this exists — the thesis

I was at a dinner in 2023 when Ozempic first came up. I mentally filed it under "Big Pharma fooling us again" and moved on. That turned out to be the wrong call — because Ozempic wasn't just a drug, it was a signal. Within eighteen months it became a $50 billion market and rearranged the entire pharmaceutical industry. But Ozempic is just one peptide. There are hundreds of others, and the same arc — from "that sounds sketchy" to "my doctor prescribed it" — is now happening across the whole category.

The "not FDA-approved" objection is understandable and mostly wrong. BPC-157 has been studied since the 1990s. GHK-Cu since the 1970s. Thymosin alpha-1 is an approved pharmaceutical in 35+ countries. The reason they're not FDA-approved in the US isn't because they're dangerous — it's because FDA approval costs hundreds of millions of dollars and you don't spend that on a molecule you can't patent. The system is producing an outcome that looks like a verdict but is actually just an incentive problem.

In 2015 peptides were a bodybuilding secret. By 2022 Huberman was discussing them with millions of listeners. In 2023 Ozempic blew the door off the hinges. Now it's 2026 and we're at the inflection point. Retatrutide — a triple-receptor agonist — destroyed semaglutide in clinical trials and almost nobody outside this world has noticed yet. This is where the internet was in the mid-1990s: the technology works, the early adopters know it, the mainstream is just starting to pay attention.

The information gap between people who understand peptides and people who don't is enormous. The window of broad, affordable access that exists right now may not exist in two years. That's why The Compound exists. The peptide revolution is here. Most people just haven't noticed yet.